# EDGAR Filing Document

**Accession Number:** 0000894158
**File Stem:** 0001104659-25-100132
**Filing Date:** 2025-10
**Character Count:** 4509
**Document Hash:** 104511adc2b5c1e45dc774139a5a3d1b
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001104659-25-100132.hdr.sgml**: 20251016

**ACCESSION NUMBER**: 0001104659-25-100132

**CONFORMED SUBMISSION TYPE**: 424B5

**PUBLIC DOCUMENT COUNT**: 2

**FILED AS OF DATE**: 20251016

**DATE AS OF CHANGE**: 20251016

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Theriva Biologics, Inc.
- **CENTRAL INDEX KEY:** 0000894158
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 133808303
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 424B5
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-283722
- **FILM NUMBER:** 251398259

**BUSINESS ADDRESS:**
- **STREET 1:** 9605 MEDICAL CENTER DRIVE
- **STREET 2:** SUITE 270
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850
- **BUSINESS PHONE:** (734) 332-7800

**MAIL ADDRESS:**
- **STREET 1:** 9605 MEDICAL CENTER DRIVE
- **STREET 2:** SUITE 270
- **CITY:** ROCKVILLE
- **STATE:** MD
- **ZIP:** 20850

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Synthetic Biologics, Inc.
- **DATE OF NAME CHANGE:** 20120305

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** ADEONA PHARMACEUTICALS, INC.
- **DATE OF NAME CHANGE:** 20081027

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** PIPEX PHARMACEUTICALS, INC.
- **DATE OF NAME CHANGE:** 20061214

**Filed pursuant to Rule 424(b)(5)**

**Registration No. 333-283722**

**Amendment No. 1 to**<br> **PROSPECTUS SUPPLEMENT NO. 1**

(to the prospectus dated May 7, 2025)

![](tm2528921d1_424b5img001.jpg)

**Theriva Biologics, Inc.**

**6,747,280 Shares of Common Stock**

This prospectus supplement updates, amends and supplements the prospectus contained in our Registration Statement on Form S-1, as amended, effective as of May 7, 2025 (as supplemented or amended from time to time, the "Prospectus") (Registration No. 333-283722) relating to the offer and sale of up to 1,990,900 shares of common stock, par value $0.001 per share (the "Common Stock"), of Theriva Biologics, Inc. (the "Company"), 6,818,180 shares of Common Stock issuable upon the exercise of 6,818,180 common warrants to purchase shares of Common Stock (the "Existing Warrants"), 4,827,280 pre-funded warrants to purchase up to 4,827,280 shares of common stock, and 11,645,460 shares of Common Stock underlying the Existing Warrants and pre-funded warrants purchased by investors in a best efforts public offering that was consummated on or about May 8, 2025. This Amendment No. 1 to the Prospectus Supplement No. 1, filed on October 16, 2025 (as amended, the "Prospectus Supplement"), in order to amend the disclosure below under "Amendments to Existing Warrants" regarding the number of Existing Warrants being amended. Capitalized terms used in this Prospectus Supplement and not otherwise defined herein have the meanings specified in the Prospectus.

This Prospectus Supplement is not complete without the Prospectus. This Prospectus Supplement should be read in conjunction with the Prospectus, which is to be delivered with this Prospectus Supplement, and is qualified by reference thereto, except to the extent that the information in this Prospectus Supplement updates or supersedes the information contained in the Prospectus. Please keep this Prospectus Supplement with your Prospectus for future reference.

Our shares of Common Stock are listed on the NYSE Capital Market under the symbol "TOVX". On October 15, 2025, the closing price for our shares of Common Stock on the NYSE Capital Market was $0.84 per share.

**Investing in our securities involves a high degree of risk. Before deciding whether to invest in our securities, you should consider carefully the risks and uncertainties under the heading "Risk Factors" beginning on page 8 of the Prospectus.**

**Neither the SEC nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of the Prospectus or this Prospectus Supplement. Any representation to the contrary is a criminal offense.**

**AMENDMENTS TO EXISTING WARRANTS**

This Prospectus Supplement is being filed to disclose the following:

On October 16, 2025, we entered into an amendment with certain holders of Existing Warrants to purchase up to 6,747,280 shares of Common Stock held in the aggregate by such holders in order to amend the exercise price under such Existing Warrants from $1.10 to $0.54 per share.

**The date of this Prospectus Supplement is October 16, 2025.**